Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ESPR Esperion Therapeutics Inc.

交易中 04-15 10:10:12 EDT

2.07

+0.02

+0.78%

最高2.12	最低2.04	成交量291.95万
今开2.05	昨收2.05	日振幅3.90%
总市值5.31亿	流通市值4.90亿	总股本2.57亿
成交额603.39万	换手率1.23%	流通股本2.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics Inc.","latestPrice":2.066,"timestamp":1776262211345,"preClose":2.05,"halted":0,"volume":2919524,"delay":0,"changeRate":0.007804878048780496,"floatShares":237000000,"shares":256810500,"eps":-0.109118,"marketStatus":"交易中","change":0.016,"latestTime":"04-15 10:10:12 EDT","open":2.05,"high":2.12,"low":2.04,"amount":6033931.1901908,"amplitude":0.039024,"askPrice":2.07,"askSize":2100,"bidPrice":2.06,"bidSize":2461,"shortable":3,"etf":0,"ttmEps":-0.109118,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1776283200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":2.05,"preHourTrading":{"tag":"盘前","latestPrice":2.05,"preClose":2.05,"latestTime":"09:29 EDT","volume":41397,"amount":85160.4263874,"timestamp":1776259770088,"change":0,"changeRate":0,"amplitude":0.058537},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.05,"latestTime":"19:59 EDT","volume":162018,"amount":333899.8868,"timestamp":1776211162541,"change":0.02,"changeRate":0.009756,"amplitude":0.019512},"volumeRatio":3.75187,"optionData":{"bulkOrders":[{"symbol":"ESPR","call":true,"expireDate":1781755200000,"strike":"3.5","timestamp":1776260955013,"price":0.15,"volume":4500,"amount":67500,"type":"-"}]},"impliedVol":1.0605,"impliedVolPercentile":0.78},"requestUrl":"/m/hq/s/ESPR","defaultTab":"news","newsList":[{"id":"1164900273","title":"Athyrium资本将自2026年1月1日起收购Esperion Therapeutics对日本大冢销售的全部特许权收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1164900273","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164900273?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:08","pubTimestamp":1775160511,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics公司宣布，Athyrium资本管理的基金已达成协议，将收购该公司对合作伙伴大冢制药在日本市场销售药品所产生的全部特许权收益。这项交易将从2026年1月1日正式生效。\n通过此次交易，Athyrium资本将获得Esperion公司基于大冢制药在日本市场销售业绩的所有特许权收益份额。这一安排为Esperion提供了前期资金支持，同时使Athyrium能够参与相关产品在日本市场的未来销售增长。\n该交易体现了专业投资机构对相关产品在日本市场商业前景的认可，也为Esperion公司优化其资金结构提供了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165904165","title":"Esperion Therapeutics Inc. 融资支持收购Enbumyst开发商Corstasis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=1165904165","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165904165?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:06","pubTimestamp":1775160393,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. 已成功获得一笔融资，该资金将专项用于支持其对Corstasis Therapeutics公司的收购。Corstasis Therapeutics是创新药物Enbumyst的研发企业。此次收购将显著增强Esperion在相关治疗领域的研发管线与市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164294805","title":"Athyrium资本管理与Esperion达成5000万美元日本特许权融资，以支持对Corstasis Therapeutics的战略收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1164294805","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164294805?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:05","pubTimestamp":1775160345,"startTime":"0","endTime":"0","summary":"Athyrium资本管理与Esperion Therapeutics Inc. (NASDAQ: ESPR) 已签署一项价值5000万美元的日本特许权融资协议。此项融资旨在为Esperion Therapeutics战略性收购Corstasis Therapeutics提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161213686","title":"Esperion Therapeutics与Athyrium基金达成协议：将获12%-33%分层特许权使用费及里程碑付款，直至投资回报达2.0倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1161213686","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161213686?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:05","pubTimestamp":1775160344,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. (ESPR) 已与Athyrium基金达成一项新的财务安排。根据协议条款，Athyrium基金将有权获得基于Esperion公司净销售额的分层特许权使用费，费率区间为12%至33%。此外，Athyrium基金还将有资格获得一系列的里程碑付款。这些财务收益将持续累积，直至Athyrium基金实现其初始投资2.0倍的回报总额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127111693","title":"Esperion Therapeutics完成对Corstasis Therapeutics的收购，凭借Enbumyst™（布美他尼鼻喷雾剂）拓展心血管产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1127111693","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127111693?lang=zh_cn&edition=full","pubTime":"2026-04-03 04:00","pubTimestamp":1775160013,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. (ESPR) 已正式完成对Corstasis Therapeutics的收购，此举显著增强了其在心血管疾病治疗领域的布局。通过此次交易，Esperion获得了Enbumyst™（布美他尼鼻喷雾剂）这一创新资产，进一步丰富了其心血管产品组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178293899","title":"HLS Therapeutics宣布Nilemdotm（Bempedoic Acid）现已在加拿大上市，用于降低心血管疾病风险患者的低密度脂蛋白胆固醇","url":"https://stock-news.laohu8.com/highlight/detail?id=1178293899","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178293899?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:07","pubTimestamp":1772712473,"startTime":"0","endTime":"0","summary":"HLS Therapeutics近日宣布，其创新药物Nilemdotm（Bempedoic Acid）已正式登陆加拿大市场。该药物专为心血管疾病风险患者设计，旨在有效降低其低密度脂蛋白胆固醇（LDL-C）水平。这一进展为加拿大高危患者提供了新的治疗选择，有望帮助改善其心血管健康管理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121001947","title":"Esperion Therapeutics与Corstasis Therapeutics宣布Esperion达成收购Corstasis的最终协议，通过Enbumyst™（布美他尼鼻喷雾剂）拓展其心血管产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1121001947","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121001947?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:01","pubTimestamp":1772535674,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics与Corstasis Therapeutics共同宣布，Esperion已达成一项收购Corstasis的最终协议。此次收购将助力Esperion通过引入Enbumyst™（布美他尼鼻喷雾剂）进一步拓展其心血管产品组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145801373","title":"Esperion Therapeutics与Alkem就仿制药专利诉讼达成和解协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1145801373","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145801373?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:07","pubTimestamp":1771333652,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. (ESPR) 宣布，已与Alkem Laboratories就后者申请仿制Nexletol和Nexlizet的简略新药申请(ANDA)所引发的专利诉讼达成和解协议。该协议成功解决了由Esperion提起的专利法律纠纷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108610909","title":"Esperion与第五家仿制药申请方达成和解协议，2040年4月19日前不得上市Nexletol及Nexlizet仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1108610909","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108610909?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:06","pubTimestamp":1771333594,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics（ESPR）已与第五家仿制药申请方签署和解协议。根据协议条款，该仿制药申请方在2040年4月19日之前，不得将Nexletol®（苯戊酸）与Nexlizet®（苯戊酸/依折麦布）的仿制版本推向市场。\n此项协议的达成，进一步巩固了Esperion核心产品组合的市场独占期。Nexletol与Nexlizet是公司用于治疗高胆固醇血症的重要产品，延长其市场独占权对公司未来的营收前景具有积极意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131211018","title":"Esperion Therapeutics与Alkem达成协议：2040年4月19日前不在美国销售Nexletol或Nexlizet仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=1131211018","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131211018?lang=zh_cn&edition=full","pubTime":"2026-02-17 21:02","pubTimestamp":1771333351,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. 宣布，已与Alkem Laboratories Limited达成一项重要协议。根据协议条款，Alkem同意在2040年4月19日之前，不在美国市场销售Nexletol（bempedoic acid）或Nexlizet（bempedoic acid and ezetimibe）的仿制版本。\n此项安排进一步巩固了Esperion核心降胆固醇药物在美国市场的独家销售权，为公司提供了长期且明确的市场独占期预期。这对于保障Esperion未来的产品收入和商业前景具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130677213","title":"Esperion Therapeutics Inc. 公布2025财年初步*美国净产品销售额预期为1.56亿至1.6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130677213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130677213?lang=zh_cn&edition=full","pubTime":"2026-01-12 07:04","pubTimestamp":1768172673,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. 近日公布了其2025财年的初步业绩展望，预计其在美国市场的净产品销售额将达到1.56亿至1.6亿美元。这一数据彰显了公司核心产品在商业化的推进下所展现出的强劲增长潜力，为未来的发展奠定了积极的基调。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142792424","title":"Esperion Therapeutics：还可根据大冢在日本的总净销售额成就获得额外的销售里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1142792424","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142792424?lang=zh_cn&edition=full","pubTime":"2025-11-21 21:06","pubTimestamp":1763730402,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics：还可根据大冢在日本的总净销售额成就获得额外的销售里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190396006","title":"Esperion Therapeutics：根据协议，Esperion因近期Otsuka的成就将获得9000万美元的近期付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1190396006","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190396006?lang=zh_cn&edition=full","pubTime":"2025-11-21 21:05","pubTimestamp":1763730316,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics：根据协议，Esperion因近期Otsuka的成就将获得9000万美元的近期付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198148930","title":"异动解读 | Esperion Therapeutics盘中大涨5.26%，新数据将在AHA科学会议上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1198148930","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198148930?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:08","pubTimestamp":1762787310,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc.今日盘中大涨5.26%，引起投资者广泛关注。根据公司最新公告，Esperion将在2025年美国心脏协会科学会议上通过口头和海报演示展示其主打产品Nexletol的最新研究数据。AHA科学会议是心血管领域最具影响力的学术会议之一，Esperion在此展示Nexletol的新数据意义重大。Nexletol是一种用于降低胆固醇的创新药物，新数据的公布可能会进一步证实其临床效果和安全性。投资者对这一潜在的积极发展做出了乐观反应，推动了Esperion股价的大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196636131","title":"Esperion宣布在2025年AHA科学会议上通过口头和海报演示展示Nexletol®（Bempedoic Acid）的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1196636131","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196636131?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:03","pubTimestamp":1762779794,"startTime":"0","endTime":"0","summary":"Esperion宣布在2025年AHA科学会议上通过口头和海报演示展示Nexletol®（Bempedoic Acid）的新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123193546","title":"Esperion Therapeutics Inc重申其对2025财年运营开支的预期在2.15亿到2.35亿美元之间","url":"https://stock-news.laohu8.com/highlight/detail?id=1123193546","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123193546?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:04","pubTimestamp":1762427078,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc重申其对2025财年运营开支的预期在2.15亿到2.35亿美元之间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106714850","title":"Esperion Therapeutics预计将于2026年第一季度实现可持续盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1106714850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106714850?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:04","pubTimestamp":1762427048,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics预计将于2026年第一季度实现可持续盈利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150423458","title":"新闻稿：Esperion任命行业资深人士John Harlow为首席商业官","url":"https://stock-news.laohu8.com/highlight/detail?id=1150423458","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150423458?lang=zh_cn&edition=full","pubTime":"2025-11-04 21:03","pubTimestamp":1762261412,"startTime":"0","endTime":"0","summary":"安阿伯，密歇根州，2025年11月4日-- Esperion今日宣布，John Harlow已被任命为公司的首席商业官，任职时间从2025年11月17日生效。Harlow先生将加入Esperion的执行领导团队，并直接向Esperion的总裁兼首席执行官Sheldon Koenig汇报。本新闻稿中包含的任何明确或隐含的非历史事实声明可能被视为前瞻性声明。本新闻稿中包含的任何前瞻性声明仅在此日期时有效，Esperion不承担任何更新或修订本新闻稿中包含的前瞻性声明的义务或承诺，除非法律要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4007","ESPR","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132902985","title":"Esperion Therapeutics Inc - Esp-2001 可能符合FDA的孤儿药和快速通道认证资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1132902985","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132902985?lang=zh_cn&edition=full","pubTime":"2025-10-16 20:08","pubTimestamp":1760616489,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc - Esp-2001 可能符合FDA的孤儿药和快速通道认证资格","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518320835","title":"Esperion Therapeutics, Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518320835","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518320835?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:52","pubTimestamp":1741618343,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时52分，Esperion Therapeutics, Inc.股票出现波动，股价大幅跳水5.03%。截至发稿，该股报1.61美元/股，成交量116.017万股，换手率0.59%，振幅5.92%。Esperion Therapeutics, Inc.股票所在的制药行业中，整体跌幅为1.97%。其相关个股中，Sonoma Pharmaceuticals, Inc.、Sunshine Biopharma Inc C/Wts 、Medicus Pharma Ltd.涨幅较大，Sonoma Pharmaceuticals, Inc.、Petros Pharmaceuticals, Inc.、苏轩堂较为活跃，换手率分别为1663.75%、24.02%、19.08%，振幅较大的相关个股有Sonoma Pharmaceuticals, Inc.、Alvotech C/Wts 、Scilex Holding Company C/Wts 10/11/2027 ，振幅分别为60.30%、41.21%、35.91%。Esperion Therapeutics, Inc.公司简介：Esperion Therapeutics Inc 是一家制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225223a26a4395&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310225223a26a4395&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4007","ESPR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.1126},{"period":"1month","weight":-0.1598},{"period":"3month","weight":-0.3653},{"period":"6month","weight":-0.2264},{"period":"1year","weight":1.0518},{"period":"ytd","weight":-0.4459}],"compareEarnings":[{"period":"1week","weight":0.0535},{"period":"1month","weight":0.0486},{"period":"3month","weight":0.0059},{"period":"6month","weight":0.0512},{"period":"1year","weight":0.2881},{"period":"ytd","weight":0.0184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Esperion Therapeutics, Inc.于2008年1月在特拉华州注册成立。该公司是一家后期制药公司，专注于开发和商业化补充，方便，具有成本效益的每日一次口服疗法，用于治疗 LDL-C升高的患者。 通过科学和临床卓越以及对胆固醇生物学的深入理解，该公司有经验的脂质管理团队致力于开发新的LDL-C降低疗法，这将对减少全球心血管疾病或心血管疾病产生重大影响; 世界各地死亡的主要原因。","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.039729},{"month":4,"riseRate":0.384615,"avgChangeRate":-0.045323},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics Inc.","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Esperion Therapeutics Inc.(ESPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Esperion Therapeutics Inc.,ESPR,Esperion Therapeutics Inc.股票,Esperion Therapeutics Inc.股票老虎,Esperion Therapeutics Inc.股票老虎国际,Esperion Therapeutics Inc.行情,Esperion Therapeutics Inc.股票行情,Esperion Therapeutics Inc.股价,Esperion Therapeutics Inc.股市,Esperion Therapeutics Inc.股票价格,Esperion Therapeutics Inc.股票交易,Esperion Therapeutics Inc.股票购买,Esperion Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics Inc.(ESPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Esperion Therapeutics Inc.(ESPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}